Justin W. Yorke
Known title: DirectorCIK: 0001361896
Justin W. Yorke's purchase track record
Justin W. Yorke has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/27/2025 | PCSA | $10K | -61.6% | -62.1% | +6.3% |
| 1/30/2024 | PCSA | $22K | -19.3% | -15.6% | +10.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| PCSA | ▲ Buy | Option Exercise | 203 | — | 6/26/2026 | View on chart |
| PCSA | ▲ Buy | Open Market | 12,400 | $10K | 1/27/2025 | View on chart |
| PCSA | ▲ Buy | Open Market | 8,000 | $22K | 1/30/2024 | View on chart |
| PCSA | ▼ Sell | Other | 55,267 | $0 | 11/21/2023 | View on chart |
| PCSA | ▲ Buy | Grant | 6,000 | $2K | 10/12/2023 | View on chart |
| PCSA | ▲ Buy | Grant | 12,000 | $3K | 10/10/2023 | View on chart |
| PCSA | ▲ Buy | Option Exercise | 23,636 | — | 6/27/2023 | View on chart |
| PCSA | ▲ Buy | Grant | 18,208 | — | 12/31/2022 | View on chart |
| PCSA | ▲ Buy | Grant | 4,393 | — | 3/31/2022 | View on chart |
| PCSA | ▲ Buy | Grant | 4,393 | — | 3/31/2022 | View on chart |
| PCSA | ▼ Sell | Open Market | 1,854 | $6K | 1/27/2022 | View on chart |
| PCSA | ▼ Sell | Open Market | 4,200 | $20K | 12/6/2021 | View on chart |
| PCSA | ▼ Sell | Open Market | 5,500 | $27K | 12/3/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Processa Files Prospectus for 306.5M Share Offering
Processa Pharmaceuticals filed a prospectus for an offering of 306.574 million common shares on behalf of selling shareholders. This large-scale secondary offering adds significant supply to the market, which may pressure the stock price. The company is currently trading near the lower end of its 52-week range, with technical indicators showing weakness.
Processa Files Prospectus for 306.5M Share Offering. Processa Pharmaceuticals filed a prospectus for an offering of 306.574 million common shares on behalf of selling shareholders. This large-scale secondary offering adds significant supply to the market, which may pressure the stock price. The company is currently trading near the lower end of its 52-week range, with technical indicators showing weakness.